REVIVE-IT heart failure study resumes after safety modification HealthCanal.com ANN ARBOR, Mich. -- The University of Michigan Health System received approval from the Food and Drug Administration (FDA) on March 12 to resume the REVIVE-IT (Randomized Evaluation of VAD Intervention before Inotropic Therapy) pilot clinical trial ... |
